$2.37
0.0050.21%
Last update: 9:25 AM
15 minutes delayed
Comments
Loading...
Xeris Biopharma Holdings
XERSNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Xeris Biopharma Holdings (NASDAQ:XERS) Stock, Analyst Ratings, Price Targets, Forecasts
Xeris Biopharma Holdings Inc has a consensus price target of $4.79 based on the ratings of 7 analysts. The high is $6 issued by HC Wainwright & Co. on May 31, 2024. The low is $3 issued by Piper Sandler on May 10, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Piper Sandler, and Oppenheimer on May 31, 2024, May 10, 2024, and March 28, 2024, respectively. With an average price target of $4.67 between HC Wainwright & Co., Piper Sandler, and Oppenheimer, there's an implied 96.91% upside for Xeris Biopharma Holdings Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Piper Sandler
Oppenheimer
Craig-Hallum
SVB Leerink
1calculated from analyst ratings
Analyst Ratings for Xeris Biopharma Holdings
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/31/2024 | Buy Now | 153.16% | HC Wainwright & Co. | Oren Livnat | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2024 | Buy Now | 26.58% | Piper Sandler | David Amsellem | $4 → $3 | Reiterates | Overweight → Overweight | Get Alert |
| 03/28/2024 | Buy Now | 110.97% | Oppenheimer | Leland Gershell | → $5 | Initiates | → Outperform | Get Alert |
| 03/07/2024 | Buy Now | 153.16% | HC Wainwright & Co. | Oren Livnat | $5.5 → $6 | Maintains | Buy | Get Alert |
| 11/13/2023 | Buy Now | 132.07% | HC Wainwright & Co. | Oren Livnat | $6 → $5.5 | Maintains | Buy | Get Alert |
| 11/10/2023 | Buy Now | 68.78% | Piper Sandler | David Amsellem | $5 → $4 | Maintains | Overweight | Get Alert |
| 08/28/2023 | Buy Now | 89.87% | Craig-Hallum | Robin Garner | → $4.5 | Initiates | → Buy | Get Alert |
| 08/09/2023 | Buy Now | 153.16% | HC Wainwright & Co. | Oren Livnat | → $6 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2023 | Buy Now | 153.16% | HC Wainwright & Co. | Oren Livnat | → $6 | Reiterates | Buy → Buy | Get Alert |
| 03/09/2023 | Buy Now | 153.16% | HC Wainwright & Co. | Oren Livnat | → $6 | Reiterates | → Buy | Get Alert |
| 01/27/2023 | Buy Now | 110.97% | SVB Leerink | Roanna Ruiz | $6 → $5 | Maintains | Outperform | Get Alert |
| 10/21/2022 | Buy Now | 68.78% | Jefferies | Glen Santangelo | → $4 | Assumes | → Buy | Get Alert |
| 04/28/2022 | Buy Now | 174.26% | Craig-Hallum | Robin Garner | → $6.5 | Initiates | → Buy | Get Alert |
| 03/16/2022 | Buy Now | 153.16% | Mizuho | Vamil Divan | $8 → $6 | Maintains | Buy | Get Alert |
| 02/16/2022 | Buy Now | 153.16% | SVB Leerink | Roanna Ruiz | $8 → $6 | Maintains | Outperform | Get Alert |
| 12/31/2021 | Buy Now | 237.55% | SVB Leerink | Roanna Ruiz | $6 → $8 | Maintains | Outperform | Get Alert |
| 12/31/2021 | Buy Now | 127.85% | HC Wainwright & Co. | Oren Livnat | $4.25 → $5.4 | Maintains | Buy | Get Alert |
| 11/17/2021 | Buy Now | 153.16% | SVB Leerink | Roanna Ruiz | — | Initiates | → Outperform | Get Alert |
| 10/29/2021 | Buy Now | 68.78% | HC Wainwright & Co. | Oren Livnat | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Xeris Biopharma Holdings (XERS) stock?
The latest price target for Xeris Biopharma Holdings (NASDAQ:XERS) was reported by HC Wainwright & Co. on May 31, 2024. The analyst firm set a price target for $6.00 expecting XERS to rise to within 12 months (a possible 153.16% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Xeris Biopharma Holdings (XERS)?
The latest analyst rating for Xeris Biopharma Holdings (NASDAQ:XERS) was provided by HC Wainwright & Co., and Xeris Biopharma Holdings reiterated their buy rating.
When was the last upgrade for Xeris Biopharma Holdings (XERS)?
There is no last upgrade for Xeris Biopharma Holdings
When was the last downgrade for Xeris Biopharma Holdings (XERS)?
There is no last downgrade for Xeris Biopharma Holdings.
When is the next analyst rating going to be posted or updated for Xeris Biopharma Holdings (XERS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Xeris Biopharma Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Xeris Biopharma Holdings was filed on May 31, 2024 so you should expect the next rating to be made available sometime around May 31, 2025.
Is the Analyst Rating Xeris Biopharma Holdings (XERS) correct?
While ratings are subjective and will change, the latest Xeris Biopharma Holdings (XERS) rating was a reiterated with a price target of $6.00 to $6.00. The current price Xeris Biopharma Holdings (XERS) is trading at is $2.37, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.